In yesterday’s Wall Street session, United Therapeutics Corp (NASDAQ:UTHR) shares traded at $272.88, down -1.31% from the previous session.
UTHR stock price is now 10.60% away from the 50-day moving average and 17.60% away from the 200-day moving average. The market capitalization of the company currently stands at $12.11B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $213 to $215, Goldman Upgraded its rating from Sell to Neutral for United Therapeutics Corp (NASDAQ: UTHR). On February 05, 2024, Leerink Partners recently initiated its ‘Outperform’ rating on the stock quoting a target price of $330, while ‘Wells Fargo’ rates the stock as ‘Overweight’
In other news, ROTHBLATT MARTINE A, Director sold 1,468 shares of the company’s stock on May 21 ’24. The stock was sold for $404,947 at an average price of $275.85. Upon completion of the transaction, the Director now directly owns 130 shares in the company, valued at $35474.4. An SEC document containing details of the transaction can be found on the SEC’s website. On May 20 ’24, Director ROTHBLATT MARTINE A sold 5,732 shares of the business’s stock. A total of $1,574,825 was realized by selling the stock at an average price of $274.74. This leaves the insider owning 130 shares of the company worth $35474.4. A total of 7.02% of the company’s stock is owned by insiders.
During the past 12 months, United Therapeutics Corp has had a low of $204.44 and a high of $279.98. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 3.77, and a quick ratio of 3.64. According to the stock market information, the enterprise value for the company is $9995981824, which is based on a 12.90 price-to-earnings ratio, a 1.33 price-to-earnings-growth ratio, and a beta of 0.49. The fifty day moving average price for UTHR is $247.414 and a two-hundred day moving average price translates $232.23755 for the stock.
The latest earnings results from United Therapeutics Corp (NASDAQ: UTHR) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at 5.24, beating analysts’ expectations of 4.5 by 0.74. This compares to $4.86 EPS in the same period last year. The net profit margin was 42.05% and return on equity was 20.08% for UTHR. The company reported revenue of $677.7 million for the quarter, compared to $506.9 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 33.7 percent. For the current quarter, analysts expect UTHR to generate $682.29M in revenue.
